Cornerstone Therapeutics Reports Year Ended December 31, 2008 Financi...(ase. We anticipate that subsequent even...)

Date:3/26/2009

ase. We anticipate that subsequent events and developments will cause our expectations and beliefs to change. However, while we may elect to update these forward-looking statements publicly at some point in the future, we specifically disclaim any obligation to do so, whether as a result of new information, future events or otherwise. Our forward-looking statements do not reflect the potential impact of any future acquisitions, mergers, dispositions, business development transactions, joint ventures or investments that we may make. These forward-looking statements should not be relied upon as representing our views as of any date after the date of this release.

ZYFLO CR(R), ZYFLO(R), AlleRx(R), Deconsal(R), Balacet(R) and HyoMax(R) are trademarks or service marks of Cornerstone Therapeutics Inc. SPECTRACEF is a trademark of Meiji Seika Kaisha, Ltd. and is licensed to the Company.

FINANCIAL TABLES FOLLOW

                           CORNERSTONE THERAPEUTICS INC.
                        CONSOLIDATED STATEMENTS OF INCOME
                  (In thousands, except share and per share data)
                                  (Unaudited)

                                                 Year Ended December 31,
                                                   2008          2007

    Net revenues                                 $64,867       $28,071
    Costs and expenses:
      Cost of product sales (exclusive of
       amortization of product rights)             5,951         3,300
      Sales and marketing                         16,993        10,391
      Royalties                                   16,193         3,409
      General and administrative                   9,757         4,177
      Research and development                     3,838           948
      Amortization of product rights               1,334         3,160
      Other charges                       
'/>"/>
SOURCE  Cornerstone Therapeutics Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 
Related biology technology :

1. Cornerstone Therapeutics to Host Quarter and Year Ended December 31, 2008 Conference Call
2. Cornerstone Therapeutics Provides Update on Integration Activities and Issues 2008 Revenue Guidance
3. Cell Therapeutics, Inc. Reports Outcome of Special Meeting of Shareholders
4. Cell Therapeutics, Inc. Special Meeting in Lieu of Annual Meeting of Shareholders Scheduled for Tuesday, March 24, 2009
5. Cell Therapeutics Announces Filing of Form 10-K
6. Horizon Therapeutics Selected to Present at InsideVentures Debut Investor Conference March 25-26, Santa Barbara, California
7. Oxygen Biotherapeutics, Inc. Expands Board of Directors
8. Micromet Adds Sir Walter Bodmer and Bernard Fox to Its Advisory Panel for BiTE Antibody Therapeutics
9. Cell Therapeutics Presents Corporate Highlights at Invest Northwest Conference
10. Nile Therapeutics Announces Information in Compliance With NASDAQ Marketplace Rule 4350 and Reiterates 2009 Objectives
11. Medarex to Present at the Needham Cancer Therapeutics Conference